Unum Therapeutics acquires kinase inhibitors developer Kiq

Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development of precision kinase inhibitors, in an all-stock deal. Focused on developing therapies for solid tumors, Unum Therapeutics, through the deal gains access to a clinical-stage compound called PLX9486, which is a selective KIT D816V inhibitor. More...

by pharmanewsdaily | Published 4 days ago
By pharmanewsdaily On Monday, July 6th, 2020
0 Comments

Gilead Sciences announces Veklury EU approval for COVID-19 treatment

Veklury EU approval : Gilead Sciences said that Veklury (remdesivir) has been given conditional marketing authorization from  European Commission as a treatment for SARS-CoV-2 infection, the virus behind COVID-19. According More...

By pharmanewsdaily On Saturday, July 4th, 2020
0 Comments

ViiV Healthcare bags Rukobia FDA approval for HIV patients with limited treatment options

Rukobia FDA approval : ViiV Healthcare said that the US Food and Drug Administration (FDA) has approved Rukobia (fostemsavir), 600 mg extended-release tablets as a new treatment of HIV patients having limited treatment More...

By pharmanewsdaily On Saturday, July 4th, 2020
0 Comments

Medivir gets orphan medicinal product designation for MIV-818 for HCC in EU

Swedish biotech company Medivir has secured orphan medicinal product designation from the European Commission for MIV-818 for the treatment of hepatocellular carcinoma (HCC). The orphan medicinal product designation More...

By pharmanewsdaily On Friday, July 3rd, 2020
0 Comments

BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase More...

By pharmanewsdaily On Thursday, July 2nd, 2020
0 Comments

China’s CF PharmTech raises $50m in Series F round for inhalation products

CF PharmTech, a Chinese pharma company, has raised $50 million in a Series F financing round to accelerate the commercialization of its inhalation products. The investors who took part in the Series F funding round More...

By pharmanewsdaily On Tuesday, June 30th, 2020
0 Comments

India-based Piramal Pharma secures $490m investment from Carlyle Group

The Carlyle Group has signed a deal worth around $490 million with Piramal Enterprises, to acquire a stake of 20% from the Indian conglomerate’s pharma business – Piramal Pharma. The US-based private More...

By pharmanewsdaily On Monday, June 29th, 2020
0 Comments

Celltex Therapeutics gets FDA nod for Covid-19 stem cell clinical trial

Covid-19 stem cell clinical trial : Celltex Therapeutics has been given the clearance by the US Food and Drug Administration (FDA) to move ahead with a phase 2 clinical trial for investigating the efficacy of autologous More...

By pharmanewsdaily On Sunday, June 28th, 2020
0 Comments

Masimo gets FDA clearance for Centroid patient monitoring sensor

Masimo, a US medical device company, has received clearance from the US Food and Drug Administration (FDA) for Centroid, the company’s wearable, wireless patient orientation, activity, and respiration rate More...

By pharmanewsdaily On Sunday, June 28th, 2020
0 Comments

EC approves Reblozyl for transfusion-dependent anemia in adults

Bristol Myers Squibb and Acceleron Pharma have secured approval from the European Commission (EC) for their jointly developed erythroid maturation agent Reblozyl (luspatercept) for the treatment of transfusion-dependent More...